Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Active:	Yes
Cancer Type:	Unknown Primary	NCT ID:	NCT07252232
Trial Phases:	Phase III	Protocol IDs:	RMC-6236-304 (primary) NCI-2026-00629
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Revolution Medicines, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT07252232

Summary

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON)
inhibitor compared to standard of care (SOC) observation only.

Objectives

This is a global, randomized, open-label, Phase 3 study designed to evaluate whether
treatment with daraxonrasib will improve disease-free survival (DFS) compared to SOC
observation in patients with resected PDAC who have completed neoadjuvant and/or adjuvant
chemotherapy.

Treatment Sites in Georgia

Emory University Hospital - Midtown
550 Peachtree Street NE
Atlanta, GA 30308
404-686-4411
www.emoryhealthcare.org

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.